VX-702

DB05470InvestigationalSmall molecule

VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702... In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.

Mechanism: This p38 MAP kinase inhibitor effectively inhibits LPS-stimulated TNF|[alpha]|, IL-6 and IL-1|[beta]| production.
Curator reviewed
Primary indication: Investigated for use/treatment in coronary artery disease, inflammatory disorders (unspecified), and rheumatoid arthritis.Curator reviewed
Formula / weight: C₁₉H₁₂F₄N₄O₂ · 404.325 g/mol (avg)
Code names: VX-702

Resolves to

Compound

UNII527E7SK68PCAS745833-23-2ChEMBLCHEMBL1090090ChEBI94489PubChem10341154

Structure

InChIKeyFYSRKRZDBHOFAY-UHFFFAOYSA-NSMILESNC(=O)N(C1=CC=C(C(N)=O)C(=N1)C1=CC=C(F)C=C1F)C1=C(F)C=CC=C1F

Targets

Q16539MAPK14P01375TNFP01584IL1BP05231IL6

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with VX-702, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account